Cargando…
An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive digestive malignancy due to frequent late-stage diagnosis, rapid progression and resistance to therapy. With increasing PDAC incidence worldwide, there is an urgent need for new prognostic biomarkers and therapy targets. Recently, RNA me...
Autores principales: | Yun, Duo, Yang, Zhirong, Zhang, Shuman, Yang, Hai, Liu, Dongxue, Grützmann, Robert, Pilarsky, Christian, Britzen-Laurent, Nathalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437259/ https://www.ncbi.nlm.nih.gov/pubmed/36060802 http://dx.doi.org/10.3389/fcell.2022.975684 |
Ejemplares similares
-
Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer
por: Yang, Hai, et al.
Publicado: (2022) -
Pre-clinical Models of Metastasis in Pancreatic Cancer
por: Miquel, Maria, et al.
Publicado: (2021) -
CRISPR Cas9 in Pancreatic Cancer Research
por: Yang, Hai, et al.
Publicado: (2019) -
Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator
por: He, Hang, et al.
Publicado: (2022) -
Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer
por: Zhang, Jinping, et al.
Publicado: (2023)